Detecting lung cancer through blood tests that analyze tumor DNA signatures
Lung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in Blood
This study is working on a new, affordable blood test that can find early signs of lung cancer by looking for special DNA pieces from tumors in your blood, which could help catch the disease sooner and improve treatment options.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10478168 on NIH RePORTER |
What this research studies
This research focuses on developing a highly sensitive and cost-effective blood test to detect early-stage lung cancer by analyzing unique DNA fragments released by tumors into the bloodstream. The approach aims to identify these tumor-specific DNA signatures, which are rare in healthy individuals, thus minimizing false-positive results. A multidisciplinary team is utilizing advanced techniques from biochemistry, machine learning, and biostatistics to create an assay capable of detecting these low quantities of mutant DNA. This innovative method could significantly improve early detection of lung cancer, leading to better treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk for lung cancer, particularly those with a history of smoking or exposure to carcinogens.
Not a fit: Patients with advanced-stage lung cancer or those without any risk factors for lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier and more accurate detection of lung cancer, improving survival rates for patients.
How similar studies have performed: Other research has shown promise in using similar DNA analysis techniques for cancer detection, indicating potential for success in this approach.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Patel, Abhijit — Yale University
- Study coordinator: Patel, Abhijit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.